Depomed, Inc. is a specialty pharmaceutical company focused on products to treat pain and other central nervous system (CNS) conditions. The company currently markets FDA-approved products: NUCYNTA® ER (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; NUCYNTA® (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults; Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN); Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain. See Important Safety Information for NUCYNTA ER, NUCYNTA, Gralise, Cambia, and Zipsor.
Depomed has recently acquired and is developing cebranopadol, a novel, Phase III ready, first-in-class analgesic for the treatment of moderate to severe chronic nociceptive and neuropathic pain.
In addition to its ability to develop and commercialize new drugs, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.
The company’s strategy is to continue to identify, license and develop new products-that offer enhanced therapeutic options patient populations that may be underserved by existing therapies.